Records containing: Hemophilia A

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

• CLINICAL_TRIALS study record update · 2014-09-01
  A Postauthorization Safety Surveillance Study Of Patients Switching To ReFacto AF From ReFacto Or Other Factor VIII Products In Usual Care Settings
• CLINICAL_TRIALS study record update · 2014-08-21
  A Phase I, Randomized, Double-blind, Placebo Controlled, Single Dose Escalation Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors
• CLINICAL_TRIALS study record update · 2014-08-21
  KOGENATE® FS , Local Post Authorization Safety Study
• CLINICAL_TRIALS study record update · 2014-07-03
  Determination of Safety, Efficacy and Pharmacokinetics of GreenGene™ F in Previously Treated Patients 12 Years of Age or Older Diagnosed With Severe Hemophilia A
• CLINICAL_TRIALS study record update · 2014-03-14
  FEIBA NF: A Prospective, Open-label, Randomized, Parallel Study to Evaluate the Efficacy and Safety of Prophylactic Versus On-Demand Treatment in Subjects With Hemophilia A or B and a High Titer Inhibitor
• Organize your saved records without ads with Plus.
• CLINICAL_TRIALS study record update · 2014-02-11
  A Phase II/III, Randomized, Cross-over, Open-label Trial to Demonstrate Superiority of Prophylaxis Over On-demand Therapy in Previously Treated Subjects With Severe Hemophilia A Treated With Plasma Protein-free Recombinant FVIII Formulated With Sucrose (BAY 81-8973)
• CLINICAL_TRIALS study record update · 2014-01-29
  Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS
• CLINICAL_TRIALS study record update · 2014-01-17
  Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
• CLINICAL_TRIALS study record update · 2014-01-10
  Single Dose, Open-label, Randomized, Crossover Study in Subjects With Severe Hemophilia A to Compare the Bioavailability of 2 Different Strengths of Kogenate FS (BAY14-2222)
• CLINICAL_TRIALS study record update · 2014-01-06
  An Open Label Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemophilia A
• CLINICAL_TRIALS study record update · 2013-12-10
  A Prospective Non-Interventional Study to Describe Health Related Quality of Life of Youth and Young Adults With Moderate or Severe Hemophilia A Using Recombinant Factor VIII (Helixate FS).
• CLINICAL_TRIALS study record update · 2013-11-18
  A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy
• CLINICAL_TRIALS study record update · 2013-09-10
  Viscosupplementation in Patients With Hemophilic Arthropathy
• CLINICAL_TRIALS study record update · 2013-09-05
  Pharmacokinetic Comparison of 3000 IU Advate (rAHF-PFM) (Using One 3000 IU Potency Vial) With 3000 IU Advate (rAHF PFM) (Using Two 1500 IU Potency Vials) in Previously Treated Patients With Severe Hemophilia A: a Phase 4, Open-label, Prospective, Randomized, Controlled, Crossover, Multiple Center Study
• CLINICAL_TRIALS study record update · 2013-08-07
  Randomized, Controlled, Parallel, Prospective Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects, as Applicable, Compared to That of Episodic Treatment
• CLINICAL_TRIALS study record update · 2013-07-03
  Study on Von Willebrand Disease and Hemophilia in Cuenca, Ecuador
• CLINICAL_TRIALS study record update · 2013-06-11
  Rituximab for the Treatment of Inhibitors in Congenital Hemophilia A (A TMH CTN Study)
• CLINICAL_TRIALS study record update · 2013-05-14
  Optimizing Prophylaxis in Patients With Severe Haemophilia A by Tailoring the Infusions to Individual Patients' Needs Using the Calibrated Automated Thrombin Generation Test
• CLINICAL_TRIALS study record update · 2013-03-27
  A Prospective Randomized Pilot Study on the Effect of Patient Counseling on Adolescent Hemophilia Patient Compliance With Bleeding Logs
• CLINICAL_TRIALS study record update · 2013-03-26
  Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia A: a Phase IV, Prospective, Randomized, Controlled, Cross-over, Single Center Study
• CLINICAL_TRIALS study record update · 2013-02-20
  A Diagnostic Interventional, Controlled, Cross-sectional Evaluation of Joint Status Using Magnetic Resonance Imaging in Subjects With Severe Hemophilia A Treated With Primary Prophylaxis, Secondary Prophylaxis, or On-demand Therapy
• CLINICAL_TRIALS study record update · 2013-02-08
  An Open-Label, Randomized, Two-period Crossover Study To Compare Relative Bioavailability of Two Formulations of Moroctocog Alfa (Af-cc) In Subjects With Moderately Severe Or Severe Hemophilia A (FVIII:C </=2%)
• CLINICAL_TRIALS study record update · 2013-02-08
  Factor VIII Mutation Testing Program in Previously Untreated Patients (PUPs) With Hemophilia A Participating in ReFacto® Study
• CLINICAL_TRIALS study record update · 2012-12-10
  Females With Severe or Moderate Hemophilia A or B: an International Multi-center Study
• CLINICAL_TRIALS study record update · 2012-12-10
  Females With Severe or Moderate Hemophilia A or B: A Multi-Center Study